605033 Shaanxi Meibang Pharmaceutical Group
- 14.90
- -0.24-1.59%
Shaanxi Meibang Pharmaceutical Group News
Meibang Co., Ltd. (605033.SH): Wholly-owned subsidiary obtains land use rights
Gelonghui, May 14 | Meibang Co., Ltd. (605033.SH) announced that on April 27, 2024, Nuozheng Biotech won the right to use state-owned land with parcel number Puchou 2023-3-2 and signed a “Listing Transaction Confirmation” with the Pucheng County Natural Resources Bureau. Recently, Nuozheng Biotech and the Pucheng County Natural Resources Bureau signed the “State-owned Construction Land Use Rights Concession Contract” with contract number Pucheng (2024) No. 8.
We Think That There Are More Issues For Shaanxi Meibang Pharmaceutical Group (SHSE:605033) Than Just Sluggish Earnings
Following the release of a lackluster earnings report from Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033) the stock price made a strong positive move. Our analysis suggests that there a
Meibang Co., Ltd. (605033.SH): Net profit of 444.38 million yuan in the first quarter decreased 35.85% year-on-year
Gelonghui, April 29丨Meibang Co., Ltd. (605033.SH) released its first quarter report. Operating revenue was 312 million yuan, down 9.46% year on year, net profit of 444.38 million yuan, down 35.85% year on year, after deducting non-net profit of 38.39 million yuan, down 43.58% year on year, with basic earnings per share of 0.33 yuan.
Meibang Co., Ltd. (605033.SH) issued 2023 annual results, with net profit of 57.557 million yuan, a year-on-year decrease of 60.33%
Meibang Co., Ltd. (605033.SH) released its 2023 annual report. The company achieved operating income of 6 during the reporting period...
The Recent Pullback Must Have Dismayed Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033) Insiders Who Own 58% of the Company
Key Insights Significant insider control over Shaanxi Meibang Pharmaceutical Group implies vested interests in company growth 53% of the business is held by the top 2 shareholders Using data from
Shaanxi Meibang Pharmaceutical Group Co., Ltd.'s (SHSE:605033) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at Shaanxi Meibang Pharmaceutical Group's (SHSE:605033) recent performance, when its stock has declined 27% over the past three months. But if you pay close a
Meibang Co., Ltd. (605033.SH): 2023 net profit pre-reduced by 55%-64%
Gelonghui, January 29丨Meibang Co., Ltd. (605033.SH) announced the pre-reduction announcement for the 2023 annual results. According to preliminary estimates by the financial department, the company expects to achieve net profit attributable to shareholders of listed companies in 2023 of about 52-65 million yuan. Compared with the same period last year (statutory disclosure data), it will decrease by 80,000-93.09 million yuan, a year-on-year decrease of 55%-64%. In 2023, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss is expected to be approximately RMB 3604-49.04 million. Compared with the same period last year (statutory disclosure data),
Meibang Co., Ltd. (605033.SH): Received a government subsidy of 14.134,900 yuan
Gelonghui, January 2, 丨 Meibang Co., Ltd. (605033.SH) announced that from January 1, 2023 to December 29, 2023, the company and its subsidiaries and branches received a total of 14.134,900 yuan in government subsidies related to revenue, accounting for 9.7424% of the company's 2022 audited net profit attributable to shareholders of listed companies.
[Instant Analysis of BT Financial Report] Meibang Co., Ltd. 2023 Third Quarter Report: Balance Ratio Decreased, Net Cash Flow Increased Significantly
Announcement time of this financial report: 2023-10-25 17:21:17 Meibang Co., Ltd. (stock code: 605033) is an enterprise focusing on R&D, production, sales and agricultural technology promotion and service of pesticide formulations. Its main products include pesticides, fungicides, plant growth regulators, etc. The company has 25 years of deep experience in the Chinese rural market and has long been committed to promoting agricultural technology and providing services to farmers. As the top 100 sales enterprises in the national pesticide industry and the top 20 domestic pesticide formulation manufacturers, the company has good market competitiveness. According to the 2023 three-quarter report of Meibang Co., Ltd.
Meibang Co., Ltd. (605033.SH) released third-quarter results, with a net loss of 3,419,900 yuan
Meibang Co., Ltd. (605033.SH) released its report for the third quarter of 2023, with the company's operating income of 7748.6...
Meibang Pharmaceutical Earmarks 1.4 Billion Yuan for Factory Construction
Shaanxi Meibang Pharmaceutical Group (SHA:605033) plans to invest 1.38 billion yuan for the construction of a pesticide production line through subsidiary Shaanxi Nuozheng Biotechnology. The plant wil
A wholly-owned subsidiary of Meibang Co., Ltd. (605033.SH) obtained a land use right in Pucheng County to build a pesticide raw drug and intermediate production line with an annual output of 20,000 tons
Meibang Co., Ltd. (605033.SH) announced that on July 4, 2023, Shaanxi Nuozheng Biotech, a wholly-owned subsidiary of the company...
Meibang Co., Ltd. (605033.SH) released first-half results, with net profit of 73.6107 million yuan, a year-on-year decrease of 37.07%
Meibang Co., Ltd. (605033.SH) released the 2023 semi-annual report. During the reporting period, the company achieved operating income...
Meibang Co., Ltd. (605033.SH): Received an inquiry letter on the review of the application for issuance of convertible bonds
On August 7, 2023, GLONGHUI | Meibang Co., Ltd. (605033.SH) announced that on August 4, 2023, the company received the “Review and Inquiry Letter on Application Documents for Shaanxi Meibang Pharmaceutical Group Co., Ltd. to Issue Convertible Corporate Bonds to Unspecified Targets” (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange) (Shanghai Stock Exchange). The review agency of the Shanghai Stock Exchange reviewed the application documents submitted by the company to issue convertible corporate bonds to an unspecified target, and formed the first round of inquiries. The company will implement and respond item by item with relevant intermediaries in accordance with the requirements of the inquiry letter. At the same time
Meibang Co., Ltd. (605033.SH): Application to Issue Convertible Bonds Accepted by the Shanghai Stock Exchange
GLONGHUI, July 18丨Meibang Co., Ltd. (605033.SH) announced that on July 18, 2023, the company received the “Notice on Accepting the Application for Issuance of Securities by Shaanxi Meibang Pharmaceutical Group Co., Ltd. Shanghai Main Board Listed Company” issued by the Shanghai Stock Exchange (hereinafter referred to as the “Shanghai Stock Exchange”) (acceptance serial number: Shanghai Stock Exchange (Refinancing) 2023 [] No. 497). The Shanghai Stock Exchange checked the application documents submitted by the company in accordance with relevant regulations., decide It was accepted and examined in accordance with the law
Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033) Is About To Go Ex-Dividend, And It Pays A 1.2% Yield
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHSE:605033)
Meibang Co., Ltd. (605033.SH) 2022 equity distribution: 2.2 yuan for every 10 shares, equity registration on June 7
According to the Zhitong Finance App, Meibang Co., Ltd. (605033.SH) announced that the company's 2022 annual equity distribution will be implemented: a cash dividend of 2.20 yuan (tax included) for every 10 shares will be distributed to all shareholders using the company's undistributed profit. The stock registration date is June 7, 2023, and the exclusion (interest) date is June 8, 2023.
Meibang Co., Ltd. (605033.SH) announced first-quarter results, with net profit of 69.28 million yuan, a year-on-year decrease of 24.5%
According to the Zhitong Finance App, Meibang Co., Ltd. (605033.SH) disclosed its report for the first quarter of 2023. During the reporting period, the company achieved revenue of 345 million yuan, a year-on-year decrease of 29.3%; net profit of 69.28 million yuan, a decrease of 24.5% over the previous year; after deducting non-net profit of 68.05 million yuan, a decrease of 24.71% from the previous year; and basic earnings per share of 0.51 yuan.
Meibang Co., Ltd. (605033.SH): Net profit increased 15.38% to 145 million yuan in 2022, plans to distribute 10 yuan of 220 yuan
Gelonhui, April 19, 丨 Meibang Co., Ltd. (605033.SH) announced its 2022 annual report. It achieved operating income of 906 million yuan during the reporting period, an increase of 7.54% over the previous year; net profit attributable to shareholders of listed companies of 145 million yuan, an increase of 15.38% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 131 million yuan, an increase of 18.39% over the previous year; and basic earnings per share of 1.07 yuan. It is proposed to distribute a cash dividend of 2.20 yuan for every 10 shares to all shareholders using the company's undistributed profit.
Meibang Co., Ltd. (605033.SH): Plans to raise 25 million yuan to increase capital for Asia Pacific Testing
Gelonhui, April 3, 丨 Meibang Co., Ltd. (605033.SH) announced that the implementing entity of the comprehensive laboratory construction project of the fund-raising project is the subsidiary Asia Pacific Testing. The company plans to raise capital to Asia Pacific Testing by 25 million yuan, increasing the registered capital of Asia Pacific Testing by 25 million yuan. After the capital increase is completed, the registered capital of Asia Pacific Testing will increase from 50 million yuan to 75 million yuan, and the company still holds 100% of Asia Pacific Testing's shares. At the same time, the company will revise the company regulations of Asia Pacific Testing, apply for registration of industrial and commercial changes, and the subsidiary Asia Pacific Testing will implement the “Comprehensive Laboratory Construction Project” in the above fund-raising project.
Analysis
Price Target
No Data
